22h
Hosted on MSNWall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a BetShares of Atara Biotherapeutics (ATRA) have gained 11.4% over the past four weeks to close the last trading session at $8.72, but there could still be a solid upside left in the stock if short-term ...
Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara ...
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...
LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") . Such investors are advised to contact Danielle Peyton at ...
Atara Biotherapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $39.50. Atara Biotherapeutics ( NASDAQ:ATRA – Get Free Report ) last posted its quarterly earnings results on ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...
Atara Biotherapeutics, a biopharmaceutical company, disclosed plans to cut about half of its current employees. This decision comes in the wake of the Food and Drug Administration's (FDA) Complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results